NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/14/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization4,988 mln
Float185 mln
Earnings Date10/29/2026
Piotroski F-Score
1
/ 9
Very weak
1-Year Forecast
39.40
Exceptional upside
Relative Strength
47
/ 100
In line with market
Debt / Equity
0.31
Low leverage
ROE
-68.30
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Dyne Therapeutics is a US-based medical company working to develop treatments for serious muscle diseases, including myotonic dystrophy, Duchenne muscular dystrophy, and Pompe disease, among others. Founded in 2017 and based in Waltham, Massachusetts, the company uses its proprietary FORCE platform to get these treatments directly to muscle tissue where they are needed most.
